New developments in the treatment of psoriasis.
Lebwohl
Mark
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins